Global Herpes Simplex Virus Treatment Market - 2021-2028
The global herpes simplex virus Treatment Market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Herpes simplex virus (HSV) is also known for causing herpes infection. It is majorly found on genitals or the mouth and can also be seen on various body parts. There are two types of herpes simplex virus, type 1 (HSV-1) and type 2 (HSV-2), in which HSV-1 is oral herpes causing sores around lips and mouth (fever blisters or cold sores), while HSV-2 is genital herpes, wherein sores are found around genitals and rectum.
The herpes simplex virus treatment market growth is driven by the extensive research and development, growing prevalence of herpes simplex virus are the major factors responsible for the growth of this market.
The growing prevalence of herpes simplex virus, is expected to drive growth in the forecast period
According to the Centers for Disease Control and Prevention (CDC), in 2015, HSV-1 prevalence was 47.8%, while HSV-2 was 11.9% in the U.S. According to the same source, linear increase in prevalence for both HSV-1 and HSV-2 in people aged within 14-19 is 27%, for population aged within 20-29 is 41%, and for the age ranging within 30-39 and 40-49, it is 54.1% and 59.7%, respectively. According to the World Health Organization (WHO), in 2017, around 3.7 billion people (67%) under age 50 years suffered from HSV-1 infection, and 417 million (11%) people aged 15-49 years suffered from HSV-2 infection globally. This high prevalence rate has created the need for prevention and treatment of HSV, which is expected to support global herpes simplex virus (HSV) vaccines market growth.
Absence of prophylactic and therapeutic vaccine in the market is likely to hinder the market growth
Though many companies carry out clinical trials for HSV vaccines, there is an absence of prophylactic and therapeutic vaccine in the market. However, few trials have shown promising results for the prevention and treatment of HSV in clinical trials. Animal studies have shown possible results in clinical trials. However, different disease pathophysiology in animals and humans makes it difficult to produce the exact results in human trials. For example, clinical studies in mice and guinea pigs have produced more positive results than human trials, as human HSV infection is different from animal HSV infection. These factors have restricted the global herpes simplex virus (HSV) vaccine market growth.
COVID-19 Impact Analysis
Following the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries globally, and the World Health Organization has declared it a public health emergency. According to the World Health Organization's report, the coronavirus (COVID-19) manifestation has resulted in more than 52.7 million infected individuals worldwide as of November 13, 2020.
COVID-19 has affected every market globally and has also impacted the global herpes simplex virus treatment market in the following ways; by directly affecting production and demand, creating disruptions in distribution channels, and its financial impact on firms and financial markets.
Furthermore, players operating in the global herpes simplex virus treatment market face significant challenges on various fronts due to the COVID-19 pandemic. The significant challenges include the supply of raw materials for manufacturing drug formulations due to irregularities in the transportation facility. Moreover, distributors of products are experiencing irregular demand for products from the retailers due to the increasing patient population suffering from COVID-19 and other life-threatening disorders.
The GEN-003 segment is expected to hold largest share in this market segment
Genocea Biosciences, Inc. announced on May 19, 2020, entered into a material transfer agreement and exclusive license option with Shionogi & Co., Ltd. to develop a novel HSV-2 vaccine using Genocea's proprietary HSV-2 antigens from the GEN-003 program. GEN-003 is an experimental immunotherapy vaccine comprised of 2 HSV-2 proteins, glycoprotein D2. If license granted, Shionogi will assume responsibility for the global development and commercialization of the HSV-2 vaccine product. This will increase the demand for the Herpes Simplex Virus Treatment Market.
The HSV-1 (Oral Herpes) segment is expected to hold largest share in this market segment
According to the World Health Organization (WHO), regional infection prevalence estimates for HSV-1 among people range aged 0-49 years are 49% women and 39% men in the U.S., 87% women and 87% men in Africa, 69% women and 61% men in Europe, and 74% women and 73% men in western pacific are found, while for HSV-2 are found to be highest in Africa (31.5%) than compared to the U.S. (14.4%).
North America region holds the largest market share of global herpes simplex virus treatment market
North America is expected to boost herpes simplex virus (HSV) vaccines market growth during the forecast period. Several leading companies are focusing on research and development of herpes simplex virus (HSV) vaccines to prevent it. For instance, GEN-003 of Genocea Biosciences, Inc. (based in the U.S.) has shown an acceptable safety profile in phase III clinical trials in 2017, so it could be the first upcoming vaccine available for HSV the market boosting global herpes simplex virus (HSV) vaccines market growth.
The global herpes simplex virus treatment market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Sanofi S.A., GlaxoSmithKline Plc., Genocea Biosciences, Inc., Vical, Inc, Novartis, Pfizer, Abbott Laboratories, Sun Pharmaceuticals, Valeant Pharmaceuticals, Teva Pharmaceutical. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, Vical, Inc. has VCL-HB01 Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults with Symptomatic Genital HSV-2 Infection.
Herpes Simplex Virus Market Key Companies to Watch
Overview: Sanofi S.A is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013, the world's fifth-largest by prescription sales. Initially, the company was established in 1973 and merged with Synthelabo in 1999 to form Sanofi-Synthelabo. In 2004, Sanofi-Synthelabo merged with Aventis and renamed it to Sanofi-Aventis, each the product of several previous mergers. Finally, it changed its name back to Sanofi in May 2011 with 100000 employees, 69 manufacturing sites, 21 R&D sites.
Product Portfolio: The Company's portfolio comprised of Vaccines, Diabetes, Cardiovascular diseases, Neurology, Immunology, Oncology and rare diseases.
Key Developments: SP0148-Therapeutic vaccine is under Phase 1 study to treat Herpes simplex virus type 2 is developed in collaboration with Immune Design/Merck.
The global herpes simplex virus treatment market report would provide an access to an approx. 53 market data table, 42 figures and 200 pages.
Global Herpes Simplex Virus Treatment Market- By Vaccine
Global Herpes Simplex Virus Treatment Market- By Indication
Global Herpes Simplex Virus Treatment Market - By Region
LIST NOT EXHAUSTIVE